Listed

C4 Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2022

Filed with the SEC on May 5, 2022 and accepted by EDGAR at May 5, 2022, 08:16 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2022-01-01 to 2022-03-31$26.2mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2022-01-01 to 2022-03-31−$31.4mus-gaap:OperatingIncomeLoss
Income tax3 months2022-01-01 to 2022-03-31$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2022-01-01 to 2022-03-31−$31.6mus-gaap:NetIncomeLoss
Basic EPS3 months2022-01-01 to 2022-03-31−$0.65us-gaap:EarningsPerShareBasic
Operating cash flow3 months2022-01-01 to 2022-03-31−$26.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2022-01-01 to 2022-03-31$172.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-03-31$46.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-03-31$302.9mus-gaap:AssetsCurrent
Total assetsAt period end2022-03-31$515.5mus-gaap:Assets
Current liabilitiesAt period end2022-03-31$47.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-03-31$151.0mus-gaap:Liabilities
Long-term debtAt period end2022-03-31$10.2mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2022-03-31$750.0kus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2022-03-31$364.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-22-018046. Last ingested by Listed: Nov 5, 2026, 12:02 ET. Listed shows no prices and gives no investment advice.